From HandWiki - Reading time: 1 min
Saruparib is an investigational new drug that is being evaluated for the treatment of cancer.[1] It first-in-class selective inhibitor of poly-ADP ribose polymerase 1 (PARP1), designed to treat cancers with homologous recombination repair (HRR) deficiencies as a result of mutations in BRCA1, BRCA2, PALB2, RAD51C, or RAD51D genes.[2]